TY - JOUR
T1 - Tofacitinib versus methotrexate in rheumatoid arthritis
AU - Lee, Eun-Bong
AU - Fleischmann, Roy M
AU - Hall, Stephen
AU - Wilkinson, Bethanie E
AU - Bradley, John D
AU - Gruben, David
AU - Koncz, Tamas A
AU - Krishnaswami, Sriram
AU - Wallenstein, Gene V
AU - Zang, Chuanbo
AU - Zwillich, Samuel H
AU - van Vollenhoven, Ronald
PY - 2014
Y1 - 2014
N2 - Methotrexate is the most frequently used first-line antirheumatic drug. We report the findings of a phase 3 study of monotherapy with tofacitinib, an oral Janus kinase inhibitor, as compared with methotrexate monotherapy in patients with rheumatoid arthritis who had not previously received methotrexate or therapeutic doses of methotrexate.
AB - Methotrexate is the most frequently used first-line antirheumatic drug. We report the findings of a phase 3 study of monotherapy with tofacitinib, an oral Janus kinase inhibitor, as compared with methotrexate monotherapy in patients with rheumatoid arthritis who had not previously received methotrexate or therapeutic doses of methotrexate.
UR - http://www.nejm.org/doi/full/10.1056/NEJMoa1310476
U2 - 10.1056/NEJMoa1310476
DO - 10.1056/NEJMoa1310476
M3 - Article
SN - 0028-4793
VL - 370
SP - 2377
EP - 2386
JO - The New England Journal of Medicine
JF - The New England Journal of Medicine
IS - 25
ER -